SCHEMBL14067686

SCHEMBL14067686

CC(C)CCNC(=O)[C@@H](CC(C)C)NC(=O)[C@@H]1O[C@H]1C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 13/20 0.79
CTSB P07858 4/20 0.79
CAPN9 O14815 3/20 0.79
MAPK1 P28482 2/20 0.79
CTSL P07711 4/20 0.70
LMNA P02545 2/20 0.70
CTSG P08311 1/20 0.70
CTSK P43235 2/20 0.58
CTSH P09668 1/20 0.58
CTSS P25774 1/20 0.58
CTSC P53634 1/20 0.58
CYP3A4 P08684 1/20 0.58
TSHR P16473 1/20 0.58
CYP2C19 P33261 1/20 0.58
USP2 O75604 1/20 0.58
MAPT P10636 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777829 1.00 CAPN1 (0.79) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL16982381 0.93 CAPN1 (0.89) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL1121089 0.88 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL10750447 0.88 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL6041204 0.88 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL14067670 0.88 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL10933522 0.88 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL3281530 0.88 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL8219586 0.88 CAPN1 (0.81) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL14067664 0.87 CAPN1 (0.79) CAPN1CTSBCAPN9MAPK1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227806-A1 Novel Drugs for Dementia AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2008-09-18 US disclosed
US-20080227806-A1 Novel Drugs for Dementia AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2008-09-18 US disclosed
WO-2007038772-A1 NOVEL DRUGS FOR DEMENTIA AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227806-A1 Novel Drugs for Dementia CTSS, PRSS1, CBS CAPN1 273/4885CTSB 49/4885CAPN9 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.